Stay updated with breaking news from Peter Schmid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Peter Schmid, FRCP, MD, PhD, discusses key findings from the phase 1/2 BEGONIA trial in patients with unresectable, metastatic or locally advanced triple-negative breast cancer, highlighting the clinical significance of these findings.
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Oct 22, 2023--
Updated results from the BEGONIA Phase Ib/II trial for the cohort of patients treated with datopotamab deruxtecan plus Imfinzi showed that the combination demonstrated durable tumour...
WILMINGTON, Del.--(BUSINESS WIRE)--Oct 22, 2023--
Treatment with neoadjuvant pembrolizumab in combination with platinum-containing chemotherapy and followed by adjuvant pembrolizumab improved event-free survival compared with neoadjuvant chemotherapy alone in patients with high-risk triple-negative breast cancer.